Analgesics in patients with hepatic impairment: Pharmacology and clinical implications

Drugs

Volumn 72, Issue 12, 2012, Pages 1645-1669

  Bosilkovska, Marija ^a   Walder, Bernhard ^a   Besson, Marie ^a   Daali, Youssef ^a   Desmeules, Jules ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Analgesics; Liver function; Nonsteroidal anti inflammatories; Opioid analgesics; Paracetamol

Indexed keywords

ACETYLSALICYLIC ACID; ALFENTANIL; AMITRIPTYLINE; ANALGESIC AGENT; BUPRENORPHINE; CELECOXIB; CODEINE; DESIPRAMINE; DICLOFENAC; DULOXETINE; ETODOLAC; FENTANYL; HYDROMORPHONE; IBUPROFEN; IMIPRAMINE; INDOMETACIN; METHADONE; MORPHINE; NAPROXEN; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PETHIDINE; REMIFENTANIL; SUFENTANIL; SULINDAC; TAPENTADOL; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE;

ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CHRONIC PAIN; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; LIVER BLOOD FLOW; LIVER CLEARANCE; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NONALCOHOLIC FATTY LIVER; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; URINARY EXCRETION;

ANALGESICS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER DISEASES; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864712711     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635500-000000000-00000     Document Type: Review

References (188)

1. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995 Nov; 29 (5): 370-91
2. Larrey D, Pageaux G. Prescribing drugs in liver disease. In: Rodes J, Benhamou J, Blei A, editors. Textbook of he-patology: from basic science to clinical practice. Malden (MA): Blackwell Publishing, 2007: 1912-22
3. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008 Dec; 64 (12): 1147-61
4. US Department ofHealth and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired hepatic function. Study design, data analysis, and impact on dosing and labeling. 2003 May online. Available from URL: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Gui dances/UCM072123.pdfAccessed 2011 Dec 19
5. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. London: 2005 Feb 17 online. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/ Scientific-guideline/2009/ 09/WC500003122.pdfAccessed2011 Dec 19
6. Hebert MF. Guide to drug dosage in hepatic disease: Avery's drug treatment. A guide to the properties, choice, therapeutic use and economic value of drugs in disease management. 4th ed. Auckland: Adis International, 1997: 1761-89
7. LeeWM.Drug-induced hepatotoxicity.N Engl J Med 1995 Oct 26; 333 (17): 1118-27
8. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen- induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005 Dec; 42 (6): 1364-72 (Pubitemid 43260039)
9. Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med 1998 Jul 27; 105 (1B): 13S-9S (Pubitemid 28378013)
10. Lee CH, Wang JD, Chen PC Increased risk ofhospitali- zation for acute hepatitis in patients with previous ex-posure to NSAIDs. Pharmacoepidemiol Drug Saf 2010 Jul; 19 (7): 708-14
11. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003 Jul 5; 327 (7405): 18-22 (Pubitemid 36801886)
12. Laine L, White WB, Rostom A, et al. COX-2 selective in- hibitors in the treatment ofosteoarthritis. Semin Arthritis Rheum 2008 Dec; 38 (3): 165-87
13. Radner H, Ramiro S, Buchbinder R, et al. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Data-base Syst Rev 2012; 1: CD008951
14. Rossi S, Assis DN, AwsareM, etal.Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf2008; 31 (3): 261-70 (Pubitemid 351311581)
15. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999 Jul; 37 (1): 17-40
16. Blaschke TF, Rubin PC Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet 1979 Nov-Dec; 4 (6): 423-32 (Pubitemid 10210050)
17. Moreno AH, Burchell AR, Rousselot LM, et al. Portal blood flow in cirrhosis of the liver. J Clin Invest 1967 Mar; 46 (3): 436-45
18. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991 Jul; 21 (1): 42-69
19. Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharma-cokinet 2007; 46 (10): 825-50 (Pubitemid 47443308)
20. Hoyumpa AM, Schenker S. Is glucuronidation truly pre- served in patients with liver disease? Hepatology 1991 Apr; 13 (4): 786-95
21. Angus PW, Morgan DJ, Smallwood RA. Review article: hypoxia and hepatic drug metabolism. Clinical implica-tions. Aliment Pharmacol Ther 1990 Jun; 4 (3): 213-25 (Pubitemid 20377051)
22. Morgan DJ, McLean AJ. Therapeutic implications of im- paired hepatic oxygen diffusion in chronic liver disease. Hepatology 1991 Dec; 14(6): 1280-2
23. Frye RF, Zgheib NK, Matzke GR, et al. Liver disease se- lectively modulates cytochrome P450-mediated metabo-lism. Clin Pharmacol Ther 2006 Sep; 80 (3): 235-45 (Pubitemid 44313901)
24. Debinski HS, Lee CS, Danks JA, et al. Localization of ur- idine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology 1995 May; 108 (5): 1464-9
25. Mazoit JX, Sandouk P, Scherrmann JM, et al. Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 1990 Dec; 48 (6): 613-8
26. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003 Nov 29; 362 (9398): 1819-27 (Pubitemid 37494763)
27. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis: prospective stu-dy. Am J Med 1987 May; 82 (5): 945-52
28. Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983 Jun; 5 (2): 161-8 (Pubitemid 13065400)
29. Cockcroft DW, Gault MH. Prediction ofcreatinine clear- ance from serum creatinine. Nephron 1976; 16 (1): 31-41
30. Caregaro L, Menon F, Angeli P, et al. Limitations ofserum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994 Jan 24; 154 (2): 201-5 (Pubitemid 24032194)
31. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl 1979; 624: 99-105 (Pubitemid 9127210)
32. Arnman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg) 1978 Aug; 25 (4): 283-6
33. Forrest JA, Adriaenssens P, Finlayson ND, et al. Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol 1979 Jul; 15 (6): 427-31 (Pubitemid 9235912)
34. Forrest JA, Finlayson ND, Adjepon-Yamoah KK, et al. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Br Med J 1977 May 28; 1 (6073): 1384-7 (Pubitemid 8106815)
35. Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharm- acokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Phar-macol 1983; 25 (2): 253-61 (Pubitemid 13000516)
36. Williams RL, Upton RA, Cello JP, et al. Naproxen dis- position in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984; 27 (3): 291-6 (Pubitemid 15201345)
37. Juhl RP, Van Thiel DH, Dittert LW, et al. Ibuprofen and sulindac kinetics in alcoholic liver disease. Clin Pharmacol Ther 1983 Jul; 34 (1): 104-9 (Pubitemid 13073311)
38. Brater DC, Lasseter KC. Profile of etodolac: pharm- acokinetic evaluation in special populations. Clin Rheu-matol 1989 Mar; 8 Suppl. 1: 25-35 (Pubitemid 20122966)
39. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics ofcelecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000 Mar; 38 (3): 225-42 (Pubitemid 30156623)
40. Lee CR, McTavish D, Sorkin EM. Tramadol: a prelim- inary review of its pharmacodynamic and pharm-acokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993 Aug; 46 (2): 313-40 (Pubitemid 23244649)
41. Nucynta® (tapentadol) immediate-release oral tablets. US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2009 online. Available from URL: http://www.accessdata.fda.gov/drugsatfda/docs/label/ 2010/022304s003lbl.pdfAccessed 2012 May 22
42. Crotty B, Watson KJ, Desmond PV, et al. Hepatic extrac- tion of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989; 36 (5): 501-6 (Pubitemid 19135214)
43. Hasselstrom J, Eriksson S, Persson A, et al. The metabo- lism and bioavailability of morphine in patients with se-vere liver cirrhosis. Br J Clin Pharmacol 1990 Mar; 29 (3): 289-97 (Pubitemid 20129020)
44. Mazoit JX, Sandouk P, Zetlaoui P, et al. Pharmacokinetics ofunchanged morphine in normal and cirrhotic subjects. Anesth Analg 1987 Apr; 66 (4): 293-8 (Pubitemid 17060805)
45. Kotb HI, el-Kabsh MY, Emara SE, et al. Pharmacokine- tics ofcontrolled release morphine (MST) in patients with liver cirrhosis. Br J Anaesth 1997 Dec; 79 (6): 804-6 (Pubitemid 27514076)
46. Kaiko RF. Pharmacokinetics and pharmacodynamics of controlled-release opioids. ActaAnaesthesiol Scand 1997 Jan; 41 (1 Pt 2): 166-74 (Pubitemid 27072922)
47. Tallgren M, Olkkola KT, Seppala T, et al. Pharmacokine- tics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997 Jun; 61 (6): 655-61 (Pubitemid 27279927)
48. Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc 2001; 44: 83-4 (Pubitemid 34087722)
49. Neal EA, Meffin PJ, Gregory PB, et al. Enhanced bio- availability and decreased clearance ofanalgesics in patients with cirrhosis. Gastroenterology 1979 Jul; 77 (1): 96-102 (Pubitemid 9195700)
50. Pond SM, Tong T, Benowitz NL, et al. Presystemic me- tabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther 1981 Aug; 30 (2): 183-8 (Pubitemid 11039355)
51. Klotz U, McHorse TS, Wilkinson GR, et al. The effect of cirrhosis on the disposition and elimination ofmeperidine in man. Clin Pharmacol Ther 1974 Oct; 16 (4): 667-75
52. Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy 1994 Mar-Apr; 14 (2): 235-8 (Pubitemid 24108310)
53. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981 Sep; 30 (3): 353-62 (Pubitemid 11061959)
54. Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic liver disease on the disposition ofmethadone in maintenance patients. Alcohol Clin Exp Res 1985 Jul-Aug; 9 (4): 349-54 (Pubitemid 16247129)
55. Haberer JP, Schoeffler P, Couderc E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982 Dec; 54 (12): 1267-70 (Pubitemid 13203825)
56. Chauvin M, Ferrier C, Haberer JP, et al. Sufentanil pharmacokinetics in patients with cirrhosis. Anesth Analg 1989 Jan; 68 (1): 1-4 (Pubitemid 19042921)
57. Ferrier C, Marty J, Bouffard Y, et al. Alfentanil pharm- acokinetics in patients with cirrhosis. Anesthesiology 1985 Apr; 62 (4): 480-4 (Pubitemid 15111332)
58. Bower S, Sear JW, Roy RC, et al. Effects ofdifferent hepatic pathologies on disposition of alfentanil in anaes-thetized patients. Br J Anaesth 1992 May; 68 (5): 462-5
59. Baririan N, Van Obbergh L, Desager JP, et al. Alfentanil- induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007; 46 (3): 261-70 (Pubitemid 46425651)
60. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokine- tics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996 Apr; 84 (4): 812-20 (Pubitemid 26105244)
61. Navapurkar VU, Archer S, Gupta SK, et al. Metabolism of remifentanil during liver transplantation. Br J Anaesth 1998 Dec; 81 (6): 881-6 (Pubitemid 28561320)
62. Graham GG, Scott KF, Day RO. Tolerability of Paracetamol. Drug Saf2005; 28 (3): 227-40 (Pubitemid 40364889)
63. Altomare E, Vendemiale G, Albano O. Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci 1988; 43 (12): 991-8
64. Shigesawa T, Sato C, Marumo F. Significance of plasma glutathione determination in patients with alcoholic and non-alcoholic liver disease. J Gastroenterol Hepatol 1992 Jan-Feb; 7 (1): 7-11
65. Lauterburg BH. Analgesics and glutathione. Am J Ther 2002 May-Jun; 9 (3): 225-33
66. Myers RP, Shaheen AA. Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetamino-phen-related hepatotoxicity. Hepatology 2009 Apr; 49 (4): 1399-400
67. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for a-cetaminophen overdose in the United States: anationwide analysis. Hepatology 2008 Oct; 48 (4): 1336-41
68. Lee WM. Acetaminophen and the US Acute Liver Failure Study Group: lowering the risks of hepatic failure. He-patology 2004 Jul; 40 (1): 6-9 (Pubitemid 38868915)
69. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983 Jan; 33 (1): 95-101 (Pubitemid 13093755)
70. Khalid SK, Lane J, Navarro V, et al. Use of over-the- counter analgesics is not associated with acute decom-pensation in patients with cirrhosis. Clin Gastroenterol Hepatol 2009 Sep; 7 (9): 994-9; quiz 13-4
71. Dargere S, Collet T, Crampon D, et al. Lack oftoxicity of acetaminophen in patients with chronic hepatitis C: a randomized controlled trial abstract. Gastroenterology 2000; 118 (4 Part 1): A947
72. Lauterburg BH, Velez ME. Glutathione deficiency in al- coholics: risk factor for paracetamol hepatotoxicity. Gut 1988 Sep; 29 (9): 1153-7
73. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005Mar-Apr; 12(2): 133-41 (Pubitemid 40516030)
74. Girre C, Lucas D, Hispard E, et al. Assessment of cyto- chrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994 Apr 29; 47 (9): 1503-8 (Pubitemid 24167259)
75. Villeneuve JP, Raymond G, Bruneau J, et al. Pharmaco- kinetics and metabolism of acetaminophen in normal, al-coholic and cirrhotic subjects in French. Gastroenterol Clin Biol 1983 Nov; 7 (11): 898-902 (Pubitemid 14228835)
76. Zimmerman HJ, Maddrey WC. Acetaminophen (Paracetamol) hepatotoxicity with regular intake of alcohol: analysis ofinstances oftherapeuticmisadventure. Hepa-tology 1995 Sep; 22 (3): 767-73
77. Lesser PB, Vietti MM, Clark WD. Lethal enhancement of therapeutic doses of acetaminophen by alcohol. Dig Dis Sci 1986 Jan; 31 (1): 103-5 (Pubitemid 16133686)
78. Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. South Med J 1990 Sep; 83 (9): 1047-9 (Pubitemid 20294398)
79. Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000 Apr; 49 (4): 291-301 (Pubitemid 30195271)
80. Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001 Oct 8; 161 (18): 2247-52 (Pubitemid 32905006)
81. Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days ofparacetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007 Jul 15; 26 (2): 283-90 (Pubitemid 46985498)
82. Zapater P, Lasso de la Vega MC, Horga JF, et al. Pharm- acokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther 2004 Jul 1; 20 (1): 29-36 (Pubitemid 38938716)
83. Barshop NJ, Capparelli EV, Sirlin CB, et al. Acetamino- phen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011 Feb; 52 (2): 198-202
84. Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, et al. Reduction ofparacetamol and aspirin metabolism during viral hepatitis. Clin Pharmacokinet 1986 May-Jun; 11 (3): 250-6 (Pubitemid 16079743)
85. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997 Nov; 17 (6): 530-48 (Pubitemid 27465011)
86. Arroyo V, Gines P, Rimola A, et al. Renal function ab- normalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: an overview with emphasis on pathogenesis. Am J Med 1986 Aug 25; 81 (2B): 104-22 (Pubitemid 16006987)
87. Perez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabo-lism in cirrhosis. Kidney Int 1984 Jul; 26 (1): 72-80 (Pubitemid 14060591)
88. Zipser RD. Role ofrenal prostaglandins and the effects of nonsteroidal anti-inflammatory drugs in patients with li-ver disease. Am J Med 1986 Aug 25; 81 (2B): 95-103 (Pubitemid 16006986)
89. Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am J Gastroenterol 2002Aug; 97 (8): 2033-9
90. Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and as-cites: an explanation for the renal-sparing effect of su-lindac Gastroenterology 1986 Jan; 90 (1): 182-7 (Pubitemid 16211995)
91. Zipser RD, Hoefs JC, Speckart PF, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979 Jun; 48 (6): 895-900
92. Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis: relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983 Jun; 13 (3): 271-8 (Pubitemid 13100449)
93. Claria J, Kent JD, Lopez-Parra M, et al. Effects of cele- coxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005 Mar; 41 (3): 579-87 (Pubitemid 40289506)
94. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci 1987 Sep; 294 (3): 168-74 (Pubitemid 18021329)
95. Mirouze D, Zipser RD, Reynolds TB. Effect ofinhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983 Jan-Feb; 3 (1): 50-5 (Pubitemid 13175822)
96. Guevara M, Abecasis R, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites: a pilot study. Scand J Gastroenterol 2004 Apr; 39 (4): 385-6 (Pubitemid 38526728)
97. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol 2006; 47 Suppl. 1: S37-42 (Pubitemid 44651783)
98. Peck-Radosavljevic M. Review article: coagulation dis- orders in chronic liver disease. Aliment Pharmacol Ther 2007 Nov; 26 Suppl. 1: 21-8 (Pubitemid 47631866)
99. Laffi G, La Villa G, Pinzani M, et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gas-troenterology 1986 Feb; 90 (2): 274-82 (Pubitemid 16136665)
100. De Ledinghen V, Heresbach D, Fourdan O, et al. Anti- inflammatory drugs and variceal bleeding: a case-control study. Gut 1999 Feb; 44 (2): 270-3 (Pubitemid 29119373)
101. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol 2010 Dec 7; 16 (45): 5651-61
102. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepide-miol Drug Saf2006 Apr; 15 (4): 213-20
103. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and eso-phagus. Am J Med 1998 Nov 2; 105 (5A): 17S-21S
104. Li G, Treiber G, Maier K, et al. Disposition of ibuprofen in patients with liver cirrhosis: stereochemical considera-tions. Clin Pharmacokinet 1993 Aug; 25 (2): 154-63 (Pubitemid 23232395)
105. Zimmerer J, Tittor W, Degen P. Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease in German. Fortschr Med 1982 Sep 23; 100 (36): 1683-8
106. Lill JS, O'Sullivan T, Bauer LA, et al. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alco-holic cirrhosis. J Clin Pharmacol 2000 Mar; 40 (3): 250-7
107. Celebrex® (celecoxib): Compendium Suisse des Medica- ments. Zurich: Pfizer AG, 2009 online. Available from URL: http://www.compendium.ch/mpro/mnr/ 8707/html/ fr Accessed 2012 Jul 17
108. Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology 1961 Mar; 40: 389-96
109. Fraser CL, Arieff AI. Hepatic encephalopathy. N Engl J Med 1985 Oct 3; 313 (14): 865-73 (Pubitemid 15250202)
110. Bergasa NV, Rothman RB, Mukerjee E, et al. Up- regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for in-creased sensitivity to morphine in liver failure. Life Sci 2002 Feb 22; 70 (14): 1701-8 (Pubitemid 34178377)
111. Larsen FS, Wendon J. Brain edema in liver failure: basic physiologic principles and management. Liver Transpl 2002 Nov; 8 (11): 983-9 (Pubitemid 35363623)
112. Hirschfield GM, Kumagi T, Heathcote EJ. Preventative hepatology: minimising symptoms and optimising care. Liver Int 2008 Aug; 28 (7): 922-34 (Pubitemid 352044441)
113. Larson AM, Curtis Jr. Integrating palliative care for liver transplant candidates: ''too well for transplant, too sick for life''. JAMA 2006 May 10; 295 (18): 2168-76
114. Findlay JW, Jones EC, Butz RF, et al. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. Clin Pharmacol Ther 1978 Jul; 24 (1): 60-8 (Pubitemid 8407212)
115. Mignat C, Wille U, Ziegler A. Affinity profiles ofmorphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 1995; 56 (10): 793-9
116. Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41 (1): 23-6
117. Sindrup SH, Arendt-Nielsen L, Brosen K, et al. The effect ofquinidine on the analgesic effect ofcodeine. Eur J Clin Pharmacol 1992; 42 (6): 587-91
118. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990 Dec; 48 (6): 686-93
119. Girardin F, Daali Y, Gex-Fabry M, et al. Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. J Viral Hepat 2012 Aug; 19 (8): 568-73
120. Desmeules JA. The tramadol option. Eur J Pain 2000; 4 Suppl. A: 15-21 (Pubitemid 32065057)
121. Gillen C, Haurand M, Kobelt DJ, et al. Affinity, potency and efficacy oftramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000 Aug; 362 (2): 116-21 (Pubitemid 30640039)
122. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994; 47 Suppl. 1: 3-7 (Pubitemid 24132191)
123. Rollason V, Samer C, Piguet V, et al. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008 Jul; 9 (7): 905-33
124. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003 Sep; 105 (1-2): 231-8 (Pubitemid 37162492)
125. Enggaard TP, Poulsen L, Arendt-Nielsen L, et al. The an- algesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006Jan; 102(1): 146-50 (Pubitemid 43038298)
126. Kotb HI, Fouad IA, Fares KM, et al. Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag 2008 Mar-Apr; 4 (2): 99-104 (Pubitemid 351850057)
127. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R, 2R)-3-(3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid recep-tor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007 Oct; 323 (1): 265-76 (Pubitemid 47443277)
128. Xu XS, Smit JW, Lin R, et al. Population pharmacokine- tics of tapentadol immediate release (IR) in healthy sub-jects and patients with moderate or severe pain. Clin Pharmacokinet 2010 Oct; 49 (10): 671-82
129. Lugo RA, Kern SE. The pharmacokinetics ofoxycodone. J Pain Palliat Care Pharmacother 2004; 18 (4): 17-30
130. Samer CF, Daali Y, Wagner M, et al. Genetic poly- morphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010 Jun; 160 (4): 919-30
131. Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010 Jun; 160 (4): 907-18
132. Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. J Pain Palliat Care Pharmacother 2002; 16 (4): 5-18 (Pubitemid 35403706)
133. Stanski DR, Greenblatt DJ, Lowenstein E. Kinetics of in- travenous and intramuscular morphine. Clin Pharmacol Ther 1978 Jul; 24 (1): 52-9
134. Olsen GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 1975 Jun; 17 (6): 677-84
135. Patwardhan RV, Johnson RF, Hoyumpa Jr A, et al. Normal metabolism of morphine in cirrhosis. Gastro-enterology 1981 Dec; 81 (6): 1006-11 (Pubitemid 11029678)
136. Kotb HI, El-Kady SA, Emara SE, et al. Pharmacokinetics of controlled release morphine (MST) in patients with li-ver carcinoma. Br J Anaesth 2005 Jan; 94 (1): 95-9 (Pubitemid 40074915)
137. Vallner JJ, Stewart JT, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following in-travenous and oral administration to human subjects. J Clin Pharmacol 1981 Apr; 21 (4): 152-6 (Pubitemid 11073349)
138. Babul N, Darke AC, Hagen N. Hydromorphone metabo- lite accumulation in renal failure. J Pain Symptom Man-age 1995 Apr; 10 (3): 184-6
139. Paramanandam G, Prommer E, Schwenke DC Adverse effects in hospice patients with chronic kidney disease receiv-ing hydromorphone. J Palliat Med 2011 Sep; 14 (9): 1029-33
140. Michaelis M, Scholkens B, Rudolphi K. An anthology from Naunyn-Schmiedeberg's archives ofpharmacology. Naunyn Schmiedebergs Arch Pharmacol 2007 Apr; 375 (2): 81-4
141. Marinella MA. Meperidine-induced generalized seizures with normal renal function. South Med J 1997 May; 90 (5): 556-8 (Pubitemid 27376961)
142. Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure ofcancer. Ann Intern Med 1977 Jun; 86 (6): 738-41 (Pubitemid 8118769)
143. Eap CB, Buclin T, Baumann P. Interindividualvariability of the clinical pharmacokinetics of methadone: implica-tions for the treatment of opioid dependence. Clin Phar-macokinet 2002; 41 (14): 1153-93 (Pubitemid 35398691)
144. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19 (4): 13-24
145. Jiao M, Greanya ED, Haque M, et al. Methadone main- tenance therapy in liver transplantation. Prog Transplant 2010 Sep; 20 (3): 209-14; quiz 15
146. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008 Jun; 103 (6): 905-18 (Pubitemid 351703476)
147. Maxwell S, Shinderman MS, Miner A, et al. Correlation between hepatitis C serostatus and methadone dose re-quirement in 1,163 methadone-maintained patients. Her-oin Add & Rel Clin Probl 2002; 4 (2): 5-10
148. Kreek MJ, Schecter AJ, Gutjahr CL, et al. Methadone use in patients with chronic renal disease. Drug Alcohol De-pend 1980 Mar; 5 (3): 197-205 (Pubitemid 10202702)
149. Bullingham RE, McQuay HJ, Porter EJ, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982 May; 13 (5): 665-73 (Pubitemid 13139882)
150. Kuhlman Jr JJ, Lalani S, Magluilo Jr J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996 Oct; 20 (6): 369-78 (Pubitemid 26327458)
151. Elkader A, Sproule B. Buprenorphine: clinical pharmaco- kinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44 (7): 661-80 (Pubitemid 40994078)
152. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: con-sensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008 Jul-Aug; 8 (4): 287-313
153. Escher M, Daali Y, Chabert J, et al. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin Ther 2007 Aug; 29 (8): 1620-31 (Pubitemid 47494544)
154. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984 Sep-Oct; 12 (5): 577-81 (Pubitemid 14020828)
155. Walter DS, Inturrisi CE. Absorption, distribution, metab- olism and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 113-37
156. Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol He-patol2004Oct; 16(10): 1033-7 (Pubitemid 39411122)
157. Verrando R, Robaeys G, Mathei C, et al. Methadone and buprenorphine maintenance therapies for patients with hepatitis Cvirus infected after intravenous drug use. Acta Gastroenterol Belg 2005 Jan-Mar; 68 (1): 81-5 (Pubitemid 40477428)
158. Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at ther-apeutic dose. Dig Liver Dis 2009 Jul; 41 (7): e8-10
159. Petry NM, BickelWK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000 Summer; 9 (3): 265-9
160. Bogenschutz MP, Abbott PJ, Kushner R, et al. Effects of buprenorphine and hepatitis C on liver enzymes in ado-lescents and young adults. J Addict Med 2010 Dec; 4 (4): 211-6
161. Bruce RD, Altice FL. Case series on the safe use of bu- prenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007; 33 (6): 869-74 (Pubitemid 350125776)
162. Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990 Mar; 64 (3): 276-82 (Pubitemid 20119338)
163. Boger RH. Renal impairment: a challenge for opioid treatment? The role ofbuprenorphine. Palliat Med 2006; 20 Suppl. 1: s17-23 (Pubitemid 43871330)
164. Scholz J, SteinfathM, Schulz M. Clinicalpharmacokinetics of alfentanil, fentanyl and sufentanil: an update. Clin Pharmacokinet 1996 Oct; 31 (4): 275-92 (Pubitemid 26340663)
165. Jin SJ, Jung JY, Noh MH, et al. The population pharmaco- kinetics of fentanyl in patients undergoing living-donor liver transplantation. Clin Pharmacol Ther 2011 Sep; 90 (3): 423-31
166. Durogesic® Matrix (fentanyl): Compendium Suisse des Medicaments, Janssen-Cilag AG, Baar ZG, 2010; Avail-able from URL: http://www.compendium.ch/ mpro/mnr/ 6563/html/fr Accessed 2012 Jul 17
167. Murtagh FE, Chai MO, Donohoe P, et al. The use of opioid analgesia in end-stage renal disease patients man-aged without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21 (2): 5-16 (Pubitemid 47366087)
168. Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010 Jun; 11 (6): 752-8
169. King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011 Jul; 25 (5): 525-52
170. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharma-cotherapy 1997 Jul-Aug; 17 (4): 746-52 (Pubitemid 27318968)
171. Sufenta®/-forte (sufentanil): Compendium Suisse des Medicaments, Janssen-CilagAG, Baar ZG. 2010 online. Available from URL: http://www. compendium.ch/mpro/ mnr/4509/html/fr Accessed 2012 Jul 17
172. Klees TM, Sheffels P, Dale O, et al. Metabolism ofalfen- tanil by cytochrome p4503a (cyp3a) enzymes. Drug Me-tab Dispos 2005 Mar; 33 (3): 303-11 (Pubitemid 40279928)
173. Davis PJ, Stiller RL, Cook DR, et al. Effects ofcholestatic hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children. AnesthAnalg 1989 May; 68 (5): 579-83 (Pubitemid 20041742)
174. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997 Apr; 281 (1): 226-32 (Pubitemid 27203072)
175. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmaco- kinetics of remifentanil (GI87084B) and its major meta- bolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993 Nov; 79 (5): 893-903 (Pubitemid 23339046)
176. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005 Jun; 33 (3): 311-22 (Pubitemid 40903428)
177. Besson M, Piguet V, Dayer P, et al. New approaches to the pharmacotherapy of neuropathic pain. Expert Rev Clin Pharmacol 2008; 1 (5): 683-93
178. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment ofneuropathic pain: 2010 re-vision. Eur J Neurol2010 Sep; 17 (9): 1113-e88
179. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management ofneuropathic pain: evidence-based recommendations. Pain 2007 Dec 5; 132 (3): 237-51 (Pubitemid 350051570)
180. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010 Dec; 81 (12): 1372-3
181. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995 Feb; 49 (2): 280-94
182. Suri A, Reddy S, Gonzales C, et al. Duloxetine pharm- acokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther 2005 Feb; 43 (2): 78-84 (Pubitemid 40298058)
183. Vuppalanchi R, Hayashi PH, Chalasani N, et al. Dulox- etine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010 Nov; 32 (9): 1174-83
184. Andrade C, Sandarsh S, Chethan KB, et al. Sero-tonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010 Dec; 71 (12): 1565-75
185. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010 Oct; 49 (10): 661-9
186. Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011 Jun; 45 (6): e32
187. DworkinRH, O'Connor AB,Audette J, etal. Recommenda- tions for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010 Mar; 85 (3 Suppl.): S3-14
188. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis ofrandomized controlled trials. JAMA 2005 Jun 22; 293 (24): 3043-52 (Pubitemid 40965075)